Literature DB >> 27262025

Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions.

Ann-Kathrin Börger1,2, Dorothee Eicke1,2, Christina Wolf1, Christiane Gras1,2, Susanne Aufderbeck1, Kai Schulze3, Lena Engels4,2, Britta Eiz-Vesper1, Axel Schambach5,2, Carlos A Guzman3,2, Nico Lachmann5,2, Thomas Moritz5,2, Ulrich Martin4,2, Rainer Blasczyk1,2, Constança Figueiredo1,2.   

Abstract

Platelet (PLT) transfusion is indispensable to maintain homeostasis in thrombocytopenic patients. However, PLT transfusion refractoriness is a common life-threatening condition observed in multitransfused patients. The most frequent immune cause for PLT transfusion refractoriness is the presence of alloantibodies specific for human leukocyte antigen (HLA) class I epitopes. Here, we have silenced the expression of HLA class I to generate a stable HLA-universal induced pluripotent stem cell (iPSC) line that can be used as a renewable cell source for the generation of low immunogenic cell products. The expression of HLA class I was silenced by up to 82% and remained stable during iPSC cultivation. In this study, we have focused on the generation of megakaryocytes (MK) and PLTs from a HLA-universal iPSC source under feeder- and xeno-free conditions. On d 19, differentiation rates of MKs and PLTs with means of 58% and 76% were observed, respectively. HLA-universal iPSC-derived MKs showed polyploidy with DNA contents higher than 4n and formed proPLTs. Importantly, differentiated MKs remained silenced for HLA class I expression. HLA-universal MKs produced functional PLTs. Notably, iPSC-derived HLA-universal MKs were capable to escape antibody-mediated complement- and cellular-dependent cytotoxicity. Furthermore, HLA-universal MKs were able to produce PLTs after in vivo transfusion in a mouse model indicating that they might be used as an alternative to PLT transfusion. Thus, in vitro produced low immunogenic MKs and PLTs may become an alternative to PLT donation in PLT-based therapies and an important component in the management of severe alloimmunized patients.

Entities:  

Year:  2016        PMID: 27262025      PMCID: PMC5023513          DOI: 10.2119/molmed.2015.00235

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  40 in total

Review 1.  Autologous platelets as a source of proteins for healing and tissue regeneration.

Authors:  Eduardo Anitua; Isabel Andia; Bruno Ardanza; Paquita Nurden; Alan T Nurden
Journal:  Thromb Haemost       Date:  2004-01       Impact factor: 5.249

2.  Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies.

Authors:  Stephan Meinke; Per Sandgren; Anette Mörtberg; Cecilia Karlström; Nadir Kadri; Agneta Wikman; Petter Höglund
Journal:  Transfusion       Date:  2015-10-07       Impact factor: 3.157

3.  Investigation of platelet function and platelet disorders using flow cytometry.

Authors:  Peter Rubak; Peter H Nissen; Steen D Kristensen; Anne-Mette Hvas
Journal:  Platelets       Date:  2015-04-22       Impact factor: 3.862

4.  Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.

Authors:  M van Marwijk Kooy; H C van Prooijen; M Moes; I Bosma-Stants; J W Akkerman
Journal:  Blood       Date:  1991-01-01       Impact factor: 22.113

5.  The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness.

Authors:  Ashanka Beligaswatte; Eleni Tsiopelas; Ian Humphreys; Greg Bennett; Kathryn Robinson; Ken Davis; Peter Bardy
Journal:  Br J Haematol       Date:  2013-05-08       Impact factor: 6.998

Review 6.  Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness.

Authors:  Joan Cid; Laura Magnano; Maria Acosta; Cristina Alba; Jordi Esteve; Miguel Lozano
Journal:  Platelets       Date:  2014-05-27       Impact factor: 3.862

7.  Infected Nonhealing Wound in a Kidney Transplant Recipient: Successful Treatment With Topical Homologous Platelet-Rich Gel.

Authors:  Samuele Iesari; Quirino Lai; Anna Rughetti; Luigi Dell'Orso; Katia Clemente; Antonio Famulari; Francesco Pisani; Evaldo Favi
Journal:  Exp Clin Transplant       Date:  2015-06-15       Impact factor: 0.945

8.  Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.

Authors:  D Decaudin; J-M Vantelon; J-H Bourhis; F Farace; M-L Bonnet; M Guillier; N Greissenger; M-C Marracho; S Assari; A-L Bennaceur; F Némati; J Michon; A G Turhan; C Boccaccio
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

9.  Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2006-03-07       Impact factor: 4.599

Review 10.  Why has demand for platelet components increased? A review.

Authors:  L J Estcourt
Journal:  Transfus Med       Date:  2014-10       Impact factor: 2.019

View more
  31 in total

1.  Pulmonary Transplantation of Human Induced Pluripotent Stem Cell-derived Macrophages Ameliorates Pulmonary Alveolar Proteinosis.

Authors:  Christine Happle; Nico Lachmann; Mania Ackermann; Anja Mirenska; Gudrun Göhring; Kathrin Thomay; Adele Mucci; Miriam Hetzel; Torsten Glomb; Takuji Suzuki; Claudia Chalk; Silke Glage; Oliver Dittrich-Breiholz; Bruce Trapnell; Thomas Moritz; Gesine Hansen
Journal:  Am J Respir Crit Care Med       Date:  2018-08-01       Impact factor: 21.405

Review 2.  Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.

Authors:  Anja Baigger; Rainer Blasczyk; Constanca Figueiredo
Journal:  Transfus Med Hemother       Date:  2017-05-23       Impact factor: 3.747

3.  Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies.

Authors:  Nanyan Zhang; Sentot Santoso; Richard H Aster; Brian R Curtis; Peter J Newman
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

4.  Packaging functionally important plasma proteins into the α-granules of human-induced pluripotent stem cell-derived megakaryocytes.

Authors:  Nanyan Zhang; Peter J Newman
Journal:  J Tissue Eng Regen Med       Date:  2019-01-04       Impact factor: 3.963

Review 5.  Modeling genetic platelet disorders with human pluripotent stem cells: mega-progress but wanting more on our plate(let).

Authors:  Catriana C Nations; Giulia Pavani; Deborah L French; Paul Gadue
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

Review 6.  Toward in Vitro Production of Platelet from Induced Pluripotent Stem Cells.

Authors:  Elaheh Izady; Zohreh Saltanatpour; Li-Ping Liu; Akram Alizadeh; Amir Ali Hamidieh
Journal:  Stem Cell Rev Rep       Date:  2022-04-09       Impact factor: 6.692

Review 7.  Induced Pluripotent Stem Cell-Derived Megakaryocytes and Platelets for Disease Modeling and Future Clinical Applications.

Authors:  Sara Borst; Xiuli Sim; Mortimer Poncz; Deborah L French; Paul Gadue
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-10-05       Impact factor: 8.311

8.  Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors.

Authors:  Amanda L Evans; Amanda Dalby; Holly R Foster; Daniel Howard; Amie K Waller; Momal Taimoor; Moyra Lawrence; Souradip Mookerjee; Marcus Lehmann; Annie Burton; Jorge Valdez; Jonathan Thon; Joseph Italiano; Thomas Moreau; Cedric Ghevaert
Journal:  Blood Adv       Date:  2021-04-13

Review 9.  Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside.

Authors:  Daniele Focosi; Giovanni Amabile
Journal:  Cells       Date:  2017-12-27       Impact factor: 6.600

Review 10.  Process analysis of pluripotent stem cell differentiation to megakaryocytes to make platelets applying European GMP.

Authors:  Moyra Lawrence; Amanda Evans; Thomas Moreau; Marta Bagnati; Matthew Smart; Enas Hassan; Jahid Hasan; Monica Pianella; Julie Kerby; Cedric Ghevaert
Journal:  NPJ Regen Med       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.